News

Delamanid approved for use in the European Union

29 Apr 2014
by Working Group
Announcements Regulations and Guidelines TB Drug Development TB News TB Treatment Uncategorized
markets mdr otsuka pharma press press. treatment

The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis.

The press release from Otsuka can be found here

Related Links

TB Drug Fighting Resistant Strains Wins Europe Approval

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

More News
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023

New Tools Summit in Paris this November

The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022

PAN-TB Collaboration Announces Novel TB Drug Regimens Trial

The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...